To view any of our videos below, click the registration required button to be taken to the registration page where you will be sent the password to access all our video content to your email. If you have previously registered, enter your password on the registration page.
An Integrated Approach to cardiac safety and CiPA
This presentation will discuss why cardiac safety is so important during the drug discovery and the importance in this scenario of hERG ion channel and the more recent CiPA initiative.
Do Complex Medicines Present a Different Challenge form a Safety Perspective?
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments.
Evaluate the Toxicological Risk of Targeting Prolyl-Trna Synthetase, PRS In The Treatment of Malaria.
This presentation discusses work was carried out with MMV the not-for-profit Medicines for Malaria Venture. followed by a summary of the research done around the physiological role of the PRS target.
Improving Drug Project Success by Understanding Drug Target Safety
Join this educational webinar to learn how target safety assessments (TSAs) are used to determine the potential consequences of modulating a target and provide options on how to assess those risks.
The Evolving Role of Ion Channels in Shaping Successful Drug Discovery
This webinar will present the critical role of ion channels in drug discovery, and how this role is evolving. The listener will learn about advances in ion channel biology, experimental technologies and in vitro models, new ion channel ligands, and toxicological considerations.
Making Safety Part of Drug Design
This webinar was part of the Medicines Discovery Catapult Connects series of webinars “Is My Compound Safe?”. This webinar was recorded at the same time as “How to get your molecule into Humans” presented by Pauline Garner of Sequani.
Making Safety a Part of Drug Design – Preclinical Safety for Anti-infectives
In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic drug development.
Science Driven Design of Preclinical Strategy Case by Case
This presentation was part of Alderley Park’s Science Seminar Series.
Challenges and Opportunities in Toxicology
Ruth will present lessons learned from >20 years’ experience in the pharmaceutical industry focusing on attrition, prediction and the challenges posed by non-clinical to clinical concordance.